Stoic VC

Kinoxis Therapeutics is an Australian early-stage biotechnology company focused on advancing novel therapeutic compounds licensed from the University of Sydney. Its primary objective is to develop treatments for substance use disorders and other central nervous system (CNS) conditions. The company's lead candidate has shown promising anti-addictive and prosocial effects in various animal models and is currently undergoing pre-clinical testing. Kinoxis aims to address the growing need for effective therapies in this area, with a particular focus on opioid withdrawal, methamphetamine use disorder, and nicotine withdrawal.

Lenexa Medical specializes in developing innovative technology aimed at preventing pressure injuries in hospitalized patients. Their core product is a medical-grade smart sheet, an ultra-thin fabric bedsheet equipped with advanced sensing capabilities. This sheet, when used in conjunction with Lenexa's proprietary software, continuously monitors patient position and posture, thereby assessing the risk of pressure injuries. The company's services focus on providing clinicians with actionable insights to deliver targeted, long-term solutions for pressure injury detection and prevention, ultimately enhancing patient health outcomes.

BioScout develops an integrated hardware and software platform designed to detect and prevent airborne diseases in farm fields worldwide. The platform combines air sampling, mapping, data analytics, and sensors to provide real-time disease tracking, enabling farmers to maximize yield, improve spray efficiency, and proactively manage diseases.

Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, focused on transforming the treatment and prevention of respiratory infections. Incorporated in 2020, the company develops synthetic innate immunomodulators aimed at preventing respiratory viral and bacterial infections. Ena Respiratory specializes in novel Toll-like receptor 2 (TLR2) receptor agonists that activate the innate immune system within the respiratory tract. This targeted approach allows for topical delivery to the airways, effectively preventing the dissemination of infections to the lungs. The company's innovations aim to enhance the effectiveness of vaccines and safeguard patients with pre-existing lung conditions from critical complications related to respiratory diseases.

Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, focused on transforming the treatment and prevention of respiratory infections. Incorporated in 2020, the company develops synthetic innate immunomodulators aimed at preventing respiratory viral and bacterial infections. Ena Respiratory specializes in novel Toll-like receptor 2 (TLR2) receptor agonists that activate the innate immune system within the respiratory tract. This targeted approach allows for topical delivery to the airways, effectively preventing the dissemination of infections to the lungs. The company's innovations aim to enhance the effectiveness of vaccines and safeguard patients with pre-existing lung conditions from critical complications related to respiratory diseases.

Founded in 2016, Wildlife Drones specializes in designing and developing innovative animal radio-tracking systems using drones. With over two decades of experience in ecological research, the company understands the challenges in tracking highly mobile animals and has created a solution that improves signal detection and reduces labor intensity.

OccuRx is a Melbourne-based biopharmaceutical company founded in 2014 that specializes in developing innovative therapeutic strategies for treating ophthalmic disorders related to retinal fibrosis. The company focuses on creating proprietary small-molecule drugs aimed at addressing the unmet clinical needs for targeted ocular therapies. These therapies are designed to enhance visual acuity and prevent vision loss in patients suffering from inflammatory and degenerative eye diseases. By enabling healthcare professionals to prevent the growth of new and abnormal blood vessels and reduce retinal inflammation, OccuRx aims to improve outcomes for individuals affected by these conditions.

Morse Micro is a wireless semiconductor company developing low-power Wi-Fi HaLow chips for the Internet of Things. Built by Wi‑Fi pioneers and industry veterans, the company focuses on long-range, energy-efficient connectivity across IoT applications such as surveillance, access control, industrial automation, and mobile devices. Its IP and patents support the design of its chips. Headquartered in Australia with offices in China and the United States, Morse Micro aims to deliver affordable, scalable IoT connectivity for a wide range of devices.

Agerris Pty Ltd, established in 2005 and based in Chippendale, Australia, specializes in designing and manufacturing modular robotics for the agricultural industry. The company's flagship product, Swagbot, is a modular robot that autonomously monitors and addresses weed issues, detects food, herds livestock, and assesses crops using computer vision. Additionally, Agerris develops an AI-based platform, Digital Farmhand, which enables farm machinery to detect and assess weeds, count individual fruit, nuts, crops, and animals. The company's products cater to various applications, including tree crop and row crop automation, intelligent spraying, livestock monitoring, and fruit and crop detection.

Forcite Helmet Systems Pty Ltd, founded in 2013 and based in Haymarket, Australia, specializes in the manufacture of smart helmets designed to enhance motorcycle safety. The helmets incorporate advanced features such as an integrated camera system, navigation, intercom capabilities, and active noise-cancelling technology. Recognizing the inherent dangers of motorcycling, Forcite aims to significantly improve safety for riders by integrating sensor technology and a proprietary software platform called Forcite Command. By utilizing lightweight carbon fiber in their helmet designs, the company seeks to provide a disruptive solution that addresses the lack of standard safety equipment in motorcycles, ultimately making riding safer and more enjoyable.

PERKii is a producer of innovative probiotic beverages designed to deliver live and protected probiotics in a refreshing, water-based drink. Each serving contains only 26 calories and minimal sugar, making it a healthier choice for consumers. Utilizing Progel™ technology, developed by scientists at The University of Queensland, PERKii encapsulates probiotics in microgels that withstand stomach acid, ensuring their effectiveness in promoting gut health and immunity. This unique technology sets PERKii apart from traditional probiotic drinks, enhancing the overall health benefits while providing a delicious taste experience. The company aims to support consumers in managing weight and improving their overall well-being through its carefully crafted beverages.

Exonate is a biotechnology company focused on developing small molecule drugs that modulate alternative messenger RNA splicing. It specializes in ophthalmology, with a primary focus on treating diabetic retinopathy and diabetic macular oedema (DMO), as well as wet age-related macular degeneration (wAMD). The company's lead program aims to provide superior efficacy through topical agents in preclinical models of wAMD.

Q-Sera develops innovative blood collection tubes using synthetically produced snake venom-derived pro-coagulant proteins. These tubes accelerate blood clotting, rapidly producing high-quality serum for biochemical analysis, thereby enhancing laboratory efficiency and patient care.

Kinoxis Therapeutics is an Australian early-stage biotechnology company focused on advancing novel therapeutic compounds licensed from the University of Sydney. Its primary objective is to develop treatments for substance use disorders and other central nervous system (CNS) conditions. The company's lead candidate has shown promising anti-addictive and prosocial effects in various animal models and is currently undergoing pre-clinical testing. Kinoxis aims to address the growing need for effective therapies in this area, with a particular focus on opioid withdrawal, methamphetamine use disorder, and nicotine withdrawal.

Nexgen Plants is a company specializing in developing non-GMO plant traits. It uses proprietary technology to create crops resistant to viruses, fungi, and salt, as well as those with enhanced nutritional content or aroma. These innovations aim to improve yields and adaptability for agriculture-dependent communities worldwide.

Certa offers an automated SaaS platform for managing third-party relationships in business-to-business interactions. Its integrated suite of products covers on-boarding, due diligence, risk mitigation, and ongoing monitoring.

Kinoxis Therapeutics is an Australian early-stage biotechnology company focused on advancing novel therapeutic compounds licensed from the University of Sydney. Its primary objective is to develop treatments for substance use disorders and other central nervous system (CNS) conditions. The company's lead candidate has shown promising anti-addictive and prosocial effects in various animal models and is currently undergoing pre-clinical testing. Kinoxis aims to address the growing need for effective therapies in this area, with a particular focus on opioid withdrawal, methamphetamine use disorder, and nicotine withdrawal.

Cardihab Pty Ltd., established in 2016 and based in Fortitude Valley, Australia, specializes in digital cardiac rehabilitation solutions. It offers a cloud-based portal and smartphone app, enabling clinicians to manage patient data, track goals, and connect to sensors. This allows for remote cardiac rehabilitation, reducing the need for frequent clinic visits and making the process more convenient and flexible for patients.

QUE Oncology, Inc. is a biopharmaceutical company that specializes in drug development and therapies for various types of cancer, including breast and prostate cancer. Founded in 2013 and based in Atlanta, Georgia, QUE Oncology was established through a collaboration between Emory University and The University of Queensland's research commercialization entity, UniQuest. The company focuses on licensing intellectual property derived from significant research discoveries at both institutions. Its lead drug candidate, Q-122, is a non-hormonal small molecule currently in Phase 1b clinical development, specifically targeting hot flashes in women undergoing anti-estrogen therapy for breast cancer. QUE Oncology also explores additional cancer research initiatives aimed at addressing unmet medical needs related to prostate cancer, melanoma, and cancer-related pain.

Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, focused on transforming the treatment and prevention of respiratory infections. Incorporated in 2020, the company develops synthetic innate immunomodulators aimed at preventing respiratory viral and bacterial infections. Ena Respiratory specializes in novel Toll-like receptor 2 (TLR2) receptor agonists that activate the innate immune system within the respiratory tract. This targeted approach allows for topical delivery to the airways, effectively preventing the dissemination of infections to the lungs. The company's innovations aim to enhance the effectiveness of vaccines and safeguard patients with pre-existing lung conditions from critical complications related to respiratory diseases.

Smart Sparrow is an e-learning platform that facilitates the creation of interactive and adaptive courseware for a variety of subjects, including digital literacy, computer sciences, finance, and soft skills. Founded in 2010 by Ariel Shoham, Dror Ben-Haim, Shaowei Ho, and Zack Belinson, the company is headquartered in Surry Hills, Australia, with an additional office in San Francisco, California. Smart Sparrow's platform features a dynamic, drag-and-drop authoring tool compatible with any web browser, allowing educators to design personalized learning experiences. This tool enables real-time collaboration and provides access to pre-made templates, streamlining the course creation process. The company serves a diverse range of institutions both locally and internationally.